Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

AMF Regulated Information

AMF Documents
AMF Press Releases

AMF Documents
AMF Press Releases

AMF Documents

Search Filings

Found 191 Results

Page 3 of 20«1 234 5...10 20...»Last »

September 26, 2022

Efficacy of Epicutaneous Immunotherapy With ViaskinTM Peanut for 4 to 7-Year-Old Peanut-Allergic Children in a Phase 3 Clinical Trial (PEPITES)

July 20, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

June 9, 2022

Securities Note – 2022

June 9, 2022

Amendment to the 2021 URD

May 17, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

May 5, 2022

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

April 14, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022

March 11, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022

March 9, 2022

DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

March 9, 2022

Page 3 of 20«1 234 5...10 20...»Last »

Latest AMF Press Releases

January 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

July 28, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 11, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

View All Press Releases

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top